Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 50% Gains Investing -- Ignore unavailable to you. Want to Upgrade?

To: Dave Gore who wrote (10641)	9/21/1999 9:28:00 PM
From: David Smith	Read Replies (2) \| Respond to of 118717

Very interesting microcap idea for the thread: Take a look at the chart on AIMM. This biotech got destroyed a few weeks ago when they discontinued trials for Colloral, a drug to treat rheumatoid arthritis. The trials were discontinued because the results did not meet extremely specific endpoints....but the drug DID show significant results. It reportedly did help many patients in the trials. HERE'S THE INTERESTING PART: on AIMM's website at www.autoimmuneinc.com, a notice just was posted: "If you are interested in purchasing Colloral if it becomes available as a nutritional supplement, use the Buy Colloral link to the left or click here." This stock is trading at cash value, it owns numerous patents, and it still has other drugs in the pipeline. In addition, it is collecting ongoing payments from Teva for another project. If AIMM decides to market Colloral as a dietary supplement, in my opinion it could be huge. Without a doubt, a larger company would be interested in such a product. Obviously, it is much harder to get a drug approved than it is to market a dietary supplement. If any news develops regarding a dietary supplement, I think AIMM could get back to the $3 level...it closed today at 65 cents.